Bernard Erickson, MD
Interventional Cardiology · St Cloud, MNNPI 1306848122
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 6 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 4 manufacturers reported payments, led by Reflow Medical Inc at 41.8% of the total. That places this record below the midpoint for interventional cardiology clinicians in MN, where the typical reported total is $5,396.
Across 6 payments — averaging $32.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Reflow Medical Inc$81
- Boston Scientific$50
- Abiomed$35
- Biotronik Inc.$28
Across 54 payments — averaging $7150.63 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Amgen$191K
- Novartis$117K
- Kowa Research Institute, Inc.$39K
- AstraZeneca$12K
- Amarin Pharma, Inc.$11K
- Bayer$7K
- plus $8K from 2 others
What the payments were for
- Food & beverage$195100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Reflow Medical Inc | 1 | $81 |
| Boston Scientific | 2 | $50 |
| Abiomed | 2 | $35 |
| Biotronik Inc. | 1 | $28 |
How this compares
$195 in reported general payments places this provider in the 10th percentile of 84 interventional cardiology providers in Minnesota.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 67 | $83,181 |
| Repatha SureclickEvolocumab | 35 | $48,503 |
| XareltoRivaroxaban | 39 | $46,682 |
| EntrestoSacubitril/Valsartan | 23 | $24,188 |
| BrilintaTicagrelor | 24 | $13,506 |
| ClopidogrelClopidogrel Bisulfate | 501 | $7,357 |
| Cilostazol | 186 | $5,908 |
| Metoprolol Succinate | 323 | $4,901 |
| Atorvastatin Calcium | 261 | $4,831 |
| Isosorbide Mononitrate ErIsosorbide Mononitrate | 184 | $3,722 |
| Nifedipine ErNifedipine | 91 | $2,846 |
| Flecainide Acetate | 46 | $2,353 |
| Rosuvastatin Calcium | 128 | $1,954 |
| Losartan Potassium | 164 | $1,882 |
| Lisinopril | 162 | $1,775 |
Paid to pharmacies, not to this prescriber.
Other interventional cardiology in St Cloud
- Brian StegmanSt Cloud$587K
- Jacob DutcherSt Cloud$123K
- Wade SchmidtSt Cloud$9K
- Thom DahleSaint Cloud$1.1M
- Stephen KiddSaint Cloud$607K
- Emmanouil BrilakisMinneapolis$548K
- Wesley PedersenMinneapolis$493K
- Michael ManolesMinneapolis$201K
- Jay TraverseMinneapolis$198K
- Robert WilsonMinneapolis$176K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.